FUNDAMENTALS · Fundamentals · TW Healthcare

Hi-Clearance (1788) Fundamentals 2026 — P/E 14.9x, Revenue Analysis | SniperIQ

Hi-Clearance (1788) is a TW-listed Healthcare company in Medical - Equipment & Services with a market capitalization of NT$5.8B, trading at NT

30.00 on the TWO. This SniperIQ fundamentals page covers Hi-Clearance's valuation (P/E 14.9x, P/B 1.8x), profitability (net margin 8.9%), revenue (NT$4.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT$5.8B
P/E (TTM)14.9x
Net Margin8.9%
Revenue (FY25)NT$4.3B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Hi-Clearance's market cap?

Hi-Clearance (1788) has a market capitalization of approximately NT$5.8B, trading at NT

30.00 on the TWO. Market cap moves with the live share price.

What is Hi-Clearance's P/E ratio?

Hi-Clearance's trailing twelve-month P/E ratio is 14.9x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Hi-Clearance?

Hi-Clearance runs a net profit margin of 8.9%, a gross margin of 27.1%, and an operating margin of 10.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Hi-Clearance generate?

Hi-Clearance reported revenue of NT$4.3B for fiscal year 2025, with net income of NT

69M and earnings per share (EPS) of 8.28. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Hi-Clearance pay a dividend?

Hi-Clearance offers a trailing dividend yield of about 5.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Hi-Clearance financially healthy?

Hi-Clearance carries a debt-to-equity ratio of 0.39x and a current ratio of 1.78x, with a market beta of 0.07. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Hi-Clearance a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hi-Clearance (1788) the key facts are: market cap NT$5.8B, P/E 14.9x, revenue NT$4.3B, 52-week range 129-140. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Hi-Clearance's full fundamentals live

Get Hi-Clearance's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Shanghai Kindly Medical Instruments (1501) fundamentals · Mirum Pharmaceuticals (MIRM) fundamentals · Wanbangde Pharmaceutical Holding Group (002082) fundamentals · AnnJi (7754) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons